De Michieli, Laura; Sinigiani, Giulio; Guida, Gianluigi; Saturi, Giulia; Sena, Giuseppe; Capovilla, Teresa Maria; Cantone, Anna; ... Milani, Paolo; + view all De Michieli, Laura; Sinigiani, Giulio; Guida, Gianluigi; Saturi, Giulia; Sena, Giuseppe; Capovilla, Teresa Maria; Cantone, Anna; Cianca, Alessandro; Lupi, Alessandro; Porcari, Aldostefano; Tini, Giacomo; Vergaro, Giuseppe; Cappelli, Francesco; Albertini, Riccardo; Bianco, Matteo; Mussinelli, Roberta; Serenelli, Matteo; Musumeci, Beatrice; Perlini, Stefano; Merlo, Marco; Longhi, Simone; Sinagra, Gianfranco; Perazzolo Marra, Martina; Iliceto, Sabino; Jaffe, Allan S; Palladini, Giovanni; Cipriani, Alberto; Milani, Paolo; - view fewer (2025) High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure , 18 (8) , Article e012816. 10.1161/CIRCHEARTFAILURE.125.012816.

Preview

Text High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy.pdf - Published Version Download (1MB) | Preview

Abstract

BACKGROUND: Thresholds to define prognosis with hs-cTnI (high-sensitivity cardiac troponin I) have not been systematically addressed in wild-type transthyretin amyloid cardiomyopathy, in part because of the multiplicity of hs-cTnI assays. The aims of this study were: first, to assess the prognostic performance of hs-cTnI measured with different assays in patients with wild-type transthyretin amyloid cardiomyopathy and, second, to identify assay-specific hs-cTnI thresholds for prognosis that could be integrated into staging systems for risk stratification. METHODS: Observational multicenter study of stable wild-type transthyretin amyloid cardiomyopathy patients from different cohorts using the Abbott Architect Stat hs-cTnI assay and the Beckman Coulter Access hs-cTnI assay (testing cohorts) and the Siemens Centaur XPT hs-cTnI assay (validation cohort). Outcome was all-cause mortality. RESULTS: In the Abbott cohort (n=136; median follow-up 22 [13-41] months; 31 [23%] deaths) and Beckman cohort (n=98; median follow-up 19 [12-28] months; 16 [16%] deaths), natural log-transformed hs-cTnI was an independent predictor of mortality (age- and sex-adjusted hazard ratio, 1.62 [95% CI, 1.11-2.35]; P=0.012 and 2.47 [95% CI, 1.48-4.14]; P<0.001, respectively). The best hs-cTnI threshold for 18-month mortality of the combined Abbott/Beckman cohorts (n=234) was 81 ng/L, rounded to 80 ng/L for simplicity of clinical use. A 2-variable staging system (based on the Mayo Clinic system) using hs-cTnI (>80 ng/L) and NPs (natriuretic peptides; NT-proBNP [N-terminal pro-B-type natriuretic peptide] >3000 ng/L or BNP [B-type natriuretic peptide] >250 ng/L) identified 3 groups with progressively worse prognosis. The staging system (using hs-cTnI >80 ng/L and NT-proBNP>3000 ng/L) was then applied to an independent cohort evaluated with the hs-cTnI Siemens assay (n=345, median follow-up 32 [24-42] months, 119 [34%] deaths). The significant differences between the groups were maintained. CONCLUSIONS: In patients with wild-type transthyretin amyloid cardiomyopathy, hs-cTnI is a strong and independent predictor of mortality. A threshold of hs-cTnI of 80 ng/L for these 3 assays provides effective risk stratification alone and in a staging system with NP.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item